Top Wall Street Forecasters Revamp Beyond Air Expectations Ahead Of Q4 Earnings

Benzinga
06-16

Beyond Air, Inc. (NASDAQ:XAIR) will release its fourth-quarter financial results after the closing bell on Tuesday, June 17.

Analysts expect the Garden City, New York-based company to report quarterly revenue of $1.39 million, compared to $470,000 a year earlier, according to data from Benzinga Pro.

On April 21, Beyond Air announced its NeuroNOS subsidiary was granted an FDA Orphan Drug Designation.

Beyond Air shares fell 3% to close at $0.1779 on Friday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

  • BTIG analyst Marie Thibault downgraded the stock from Buy to Neutral on June 25, 2024. This analyst has an accuracy rate of 63%.
  • Truist Securities analyst Gregory Fraser maintained a Buy rating and lowered the price target from $10 to $8 on April 30, 2024. This analyst has an accuracy rate of 63%.

Considering buying XAIR stock? Here’s what analysts think:

Read This Next:

  • Top 2 Energy Stocks That May Fall Off A Cliff in June

Photo via Shutterstock

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10